September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A METHOD FOR ROUTINE CYTOLOGICAL ASSESSMENT OF THERAPEUTIC VITRECTOMIES
Author Affiliations & Notes
  • Svetlana Cherepanoff
    Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
    Sydpath Anatomical Pathology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
  • Sonia Carbone
    Sydpath Anatomical Pathology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
  • Andrew Field
    Sydpath Anatomical Pathology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
  • Ruby Luo
    Sydpath Anatomical Pathology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia
  • Peter J McCluskey
    Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
    Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Alex Paul Hunyor
    Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
    Sydney Eye Hospital, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Svetlana Cherepanoff, None; Sonia Carbone, None; Andrew Field, None; Ruby Luo, None; Peter McCluskey, None; Alex Hunyor, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Svetlana Cherepanoff, Sonia Carbone, Andrew Field, Ruby Luo, Peter J McCluskey, Alex Paul Hunyor; A METHOD FOR ROUTINE CYTOLOGICAL ASSESSMENT OF THERAPEUTIC VITRECTOMIES. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4451.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vitreous cytology is typically requested when diagnostic vitrectomies are performed to exclude vitreoretinal lymphoma. We describe a method for routine cytological assessment of therapeutic vitrectomies.

Methods : Undiluted vitreous and vitreous washings from patients undergoing therapeutic pars plana vitrectomy (PPV) for indications including retinal detachment, macular hole, vitreous haemorrhage and epiretinal membrane were placed separately in RPMI at 1:1 dilution, kept at 4oC and transported to the cytology laboratory within 1 to 12h. Cytospin preparations were stained with Papanicolaou, Giemsa and Alcian Blue/PAS according to published methods.

Results : Cytospin preparations of undiluted vitreous and washings showed similar cellularity and cytomorphologic preservation, negating the need to separately submit undiluted vitreous in this clinical setting. A delay of up to 12 hours between collection and processing did not affect specimen quality when RPMI was used. The AB/PAS was useful for highlighting inner limiting membrane and lens capsule (PAS positive) and the hyaluronic acid component of vitreous (AB positive). Excellent cytomorphological preservation was achieved with this protocol, allowing the identification of inner limiting membrane, epiretinal membrane and its constituent cell types, pseudoexfoliation material, retinal fragments, reactive macrophages/hyalocytes, other immune cells, lens capsule and asteroid hyalosis. CD3, CD20, CD68 and GFAP immunohistochemistry was performed in selected cases; however the lack of control slides is a potential limitation of this method.

Conclusions : We describe a reliable method for cytomorphological assessment of therapeutic vitrectomies. The use of RPMI allows a delay of up to 12h between collection and processing, making this a user friendly protocol that can be readily incorporated into clinical and laboratory workflows. Routine cytological assessment of vitreous from therapeutic PPV confers the following advantages: (i) ‘tissue’ diagnosis for clinicopathological correlation; (ii) tissue auditing for surgical risk management; (iii) maintaining a laboratory skill set essential for the diagnosis of vitreoretinal lymphoma; (iv) characterisation of vitreous constituents in a range of non-neoplastic pathologies for research and potential prognostic purposes; and (v) diagnosing unsuspected pathology.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×